Jason Bednar
Stock Analyst at Piper Sandler
(2.09)
# 2,997
Out of 5,241 analysts
209
Total ratings
36.94%
Success rate
-5.28%
Average return
Main Sectors:
Stocks Rated by Jason Bednar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SHC Sotera Health Company | Reiterates: Overweight | $24 → $22 | $15.27 | +44.07% | 5 | May 6, 2026 | |
| ALGN Align Technology | Maintains: Overweight | $220 → $235 | $157.25 | +49.44% | 34 | Apr 21, 2026 | |
| SOLV Solventum | Maintains: Overweight | $98 → $92 | $74.26 | +23.89% | 9 | Apr 17, 2026 | |
| MMSI Merit Medical Systems | Maintains: Overweight | $106 → $96 | $61.31 | +56.58% | 16 | Apr 17, 2026 | |
| ICUI ICU Medical | Maintains: Overweight | $178 → $163 | $118.72 | +37.30% | 5 | Apr 17, 2026 | |
| GEHC GE HealthCare Technologies | Maintains: Overweight | $96 → $88 | $60.76 | +44.83% | 3 | Apr 17, 2026 | |
| BDX Becton, Dickinson and Company | Maintains: Neutral | $170 → $159 | $143.47 | +10.82% | 14 | Apr 17, 2026 | |
| DRTS Alpha Tau Medical | Downgrades: Neutral | $5 | $10.36 | -51.74% | 6 | Mar 4, 2026 | |
| NVST Envista Holdings | Reiterates: Neutral | $21 → $25 | $23.22 | +7.67% | 15 | Feb 6, 2026 | |
| MDLN Medline | Initiates: Overweight | $50 | $36.19 | +38.16% | 1 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $83 → $94 | $59.61 | +57.69% | 15 | Dec 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.5 → $4 | $3.90 | +2.56% | 8 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $210 | $178.44 | +17.69% | 16 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $9 → $2.5 | $1.27 | +96.85% | 12 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $34 | $17.58 | +93.40% | 11 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $16 | $10.07 | +58.89% | 8 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $83 → $77 | $72.72 | +5.89% | 7 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4.5 | $4.17 | +7.91% | 3 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $260 → $265 | $212.11 | +24.94% | 9 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $6 | $0.89 | +571.89% | 5 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $20 | $0.50 | +3,916.87% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $310 → $372 | $421.12 | -11.66% | 4 | Jan 3, 2024 |
Sotera Health Company
May 6, 2026
Reiterates: Overweight
Price Target: $24 → $22
Current: $15.27
Upside: +44.07%
Align Technology
Apr 21, 2026
Maintains: Overweight
Price Target: $220 → $235
Current: $157.25
Upside: +49.44%
Solventum
Apr 17, 2026
Maintains: Overweight
Price Target: $98 → $92
Current: $74.26
Upside: +23.89%
Merit Medical Systems
Apr 17, 2026
Maintains: Overweight
Price Target: $106 → $96
Current: $61.31
Upside: +56.58%
ICU Medical
Apr 17, 2026
Maintains: Overweight
Price Target: $178 → $163
Current: $118.72
Upside: +37.30%
GE HealthCare Technologies
Apr 17, 2026
Maintains: Overweight
Price Target: $96 → $88
Current: $60.76
Upside: +44.83%
Becton, Dickinson and Company
Apr 17, 2026
Maintains: Neutral
Price Target: $170 → $159
Current: $143.47
Upside: +10.82%
Alpha Tau Medical
Mar 4, 2026
Downgrades: Neutral
Price Target: $5
Current: $10.36
Upside: -51.74%
Envista Holdings
Feb 6, 2026
Reiterates: Neutral
Price Target: $21 → $25
Current: $23.22
Upside: +7.67%
Medline
Jan 12, 2026
Initiates: Overweight
Price Target: $50
Current: $36.19
Upside: +38.16%
Dec 5, 2025
Reiterates: Overweight
Price Target: $83 → $94
Current: $59.61
Upside: +57.69%
Aug 7, 2025
Maintains: Neutral
Price Target: $3.5 → $4
Current: $3.90
Upside: +2.56%
Aug 6, 2025
Maintains: Overweight
Price Target: $200 → $210
Current: $178.44
Upside: +17.69%
Jul 31, 2025
Downgrades: Neutral
Price Target: $9 → $2.5
Current: $1.27
Upside: +96.85%
Jun 27, 2025
Reiterates: Overweight
Price Target: $34
Current: $17.58
Upside: +93.40%
Apr 30, 2025
Maintains: Neutral
Price Target: $20 → $16
Current: $10.07
Upside: +58.89%
Apr 30, 2025
Maintains: Overweight
Price Target: $83 → $77
Current: $72.72
Upside: +5.89%
Mar 28, 2025
Maintains: Overweight
Price Target: $5 → $4.5
Current: $4.17
Upside: +7.91%
Feb 3, 2025
Maintains: Overweight
Price Target: $260 → $265
Current: $212.11
Upside: +24.94%
Nov 7, 2024
Maintains: Overweight
Price Target: $8 → $6
Current: $0.89
Upside: +571.89%
Aug 7, 2024
Maintains: Overweight
Price Target: $70 → $20
Current: $0.50
Upside: +3,916.87%
Jan 3, 2024
Maintains: Outperform
Price Target: $310 → $372
Current: $421.12
Upside: -11.66%